Order Article Reprints

Seipel K, Marques MAT, Sidler C, Mueller BU, Pabst T. The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia. Cancers. 2018; 10(6):170. https://doi.org/10.3390/cancers10060170

Seipel, Katja, Miguel A. T. Marques, Corinne Sidler, Beatrice U. Mueller, and Thomas Pabst. 2018. "The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia" Cancers 10, no. 6: 170. https://doi.org/10.3390/cancers10060170

Seipel, K., Marques, M. A. T., Sidler, C., Mueller, B. U., & Pabst, T. (2018). The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia. Cancers, 10(6), 170. https://doi.org/10.3390/cancers10060170